Physician profile
Peter G Gulick
NPI 1255383238
$849,969.32
in general payments reported to CMS, 2019-2025
25 companies · $76K in 2025
The $76K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213K · 2020: $84K · 2021: $77K · 2022: $168K · 2023: $141K · 2024: $90K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $255K · Travel and Lodging: $39K · Food and Beverage: $12K · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $255,105.00 |
| Travel and Lodging | $38,817.20 |
| Food and Beverage | $12,374.53 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $415,454.86 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $228,250.93 | 2019-2025 | Epclusa, Biktarvy, Sunlenca |
| Merck Sharp & Dohme LLC | $58,897.29 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Glaxosmithkline, LLC. | $50,073.16 | 2019-2025 | Shingrix, Arexvy, Arnuity Ellipta |
| Janssen Products, Lp | $44,559.05 | 2019-2023 | Symtuza |
| Abbvie INC. | $43,003.31 | 2019-2025 | |
| Sanofi Pasteur INC. | $4,320.00 | 2021 | |
| Theratechnologies INC. | $3,201.62 | 2019-2023 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $893.86 | 2019-2023 | Symtuza |
| Janssen Scientific Affairs, LLC | $327.83 | 2019-2023 | Symtuza |
| Vanda Pharmaceuticals INC. | $265.36 | 2022-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.07 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $103.71 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $89.50 | 2022-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $50.37 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $44.30 | 2024-2025 | Nuzyra |
| Novo Nordisk INC | $39.94 | 2025 | Ozempic |
| Pfizer INC. | $27.88 | 2023-2025 | |
| Astellas Pharma US INC | $21.56 | 2019 | |
| Allergan, INC. | $19.57 | 2020 | |
| Antares Pharma, INC. | $19.17 | 2025 | Xyosted |
| Abbott Laboratories | $16.06 | 2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $15.87 | 2021 | |
| Neurelis, INC. | $14.48 | 2023 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $13.57 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gulick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.